Pfizer Inc. (PFE)

When the stock's inexpensive, hated and devoid of love -- that's when.

Pfizer posted solid fourth quarter earnings Tuesday but issued weaker-than-expected 2019 guidance as the exclusivity of its key epilepsy treatment Lyrica comes to and end.

The Dow Jones Industrial Average posted modest gains Tuesday ahead of financial results from tech bellwether Apple Inc.

What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.

U.S. stock futures are mixed amid worries that a U.S. decision to pursue criminal charges against the chief financial officer of China's biggest tech company could stall progress in trade negotiations between the world's two biggest economies; the Fed begins a two-day meeting Tuesday; Apple, AMD, Verizon, Pfizer and 3M report earnings Tuesday; PG&E, the nation's largest utility, files for Chapter 11 bankruptcy protection.

Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2018 and provided 2019 financial guidance.

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.

Global stocks were mixed Tuesday, with Wall Street futures drifting into the red, as investors worried that a U.S. decision to pursue criminal charges against the CFO of China's biggest tech company could stall progress in trade negotiations between the world's two biggest economies that are set to resume this week.

Eight important companies report earnings between Monday and Tuesday. Don't miss them.

U.S. equity futures fell sharply lower Monday as a profit warning from industrial equipment maker Caterpillar cast a pall over the busiest week of the fourth quarter earnings season as markets shifted focus to a series of major event risks and blue chip reports in the week ahead.

Global stocks drifted lower Monday as last week's late-hour rally on Wall Street, sparked by a surprise concession from President Donald Trump to end the 35-day government shutdown, fizzled in overnight trading as markets shifted focus to a series of major event risks and blue chip corporate earnings in the day ahead.

U.S. corporate earnings have come in largely ahead of analysts' forecasts in the first two weeks of the reporting season, according to data from Refinitiv, but the rate at which companies are beating estimates continues to slip below both near and longer-term averages, suggesting the fading impact of tax cuts, and concerns about slowing global growth, could dampen profits over the first half of the year.

Jim Cramer's plan for getting through the heart of earnings season next week.

Merck and Pfizer have been laggards so far in 2019. Technical warnings occurred on Dec. 4 when both set multiyear highs and both received downgrades.

Johnson & Johnson posted stronger-than-expected fourth quarter earnings Tuesday and forecast a modest increase in full year sales for 2019 that would take its top line past $81 billion.

Big pharma is shaping up to be a consolidating category in 2019.

Jim Cramer talks about how this market is taking its cues from the positives, and shrugging off the negatives.

One of pharma's biggest CEO's talks M&A action on the exchange.

Do we have to run for the hills? Not necessarily.

Pfizer Inc. (NYSE: PFE) announced today that the US Food and Drug Administration (FDA) accepted for filing the company's New Drug Applications (NDAs) for tafamidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).

My stated reason for being in Pfizer all along has been price stability and income.

This is the kind of reversal that happens in a bull market.

Nasdaq is an American stock market and the home of stocks that make up major indexes like the Nasdaq Composite and Nasdaq 100.

We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.

BMY agreed to acquire CELG for $74 billion in cash and stock.

Pfizer Inc. (NYSE: PFE) announced today the initiation of a Phase 2b/3 clinical trial for its oral JAK3 inhibitor, PF-06651600, for the treatment of patients with moderate to severe alopecia areata, a chronic autoimmune skin disease that causes hair loss...

The health care sector may a good place to weather this storm. Here is why and how to play it.

Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chief Operating Officer, and Mikael Dolsten, President, Worldwide Research and Development, at the 37 th Annual J.

Jim Cramer explains the art and science of technical analysis.